Multiple myeloma in Niger Delta, Nigeria: complications and the outcome of palliative interventions

References

• AlexanderDDMinkPJAdamiHMultiple myeloma: a review of the epidemiologic literatureInt J Cancer2007120suppl 12406117405120
   PubMed Web of Science ®Google Scholar
• ParkinDMBrayFFerlayJPisaniPGlobal cancer statistics, 2002CA Cancer J Clin20055527410815761078
   PubMed Web of Science ®Google Scholar
• MahindraAHideshimaTAndersonKCMultiple myeloma: biology of the diseaseBlood Rev201024suppl 1S5S1121126636
   PubMed Web of Science ®Google Scholar
• RajkumarSVKyleRAMultiple myeloma: diagnosis and treatmentMayo Clin Proc200580101371138216212152
   PubMed Web of Science ®Google Scholar
• ParkinDMWhelanSLFerlayJTeppoLThomasDBCancer in Five ContinentsVIIILyonIARC2002 IARC Scientific Publication No. 155
   Google Scholar
• RiesLAGEisnerMPKosaryCL webpage on the InternetSEER Cancer Statistics Review, 1975–2002Bethesda, MDNational Cancer Institute2005 Based on November 2004 SEER data submission, posted to the SEER web site 2005; Myeloma section. Available from: http://seer.cancer.gov/csr/1975_2002/Accessed April 14, 2017
   Google Scholar
• LandgrenOKyleRAPfeifferRMMonoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma. A prospective studyBlood2009113225412541719179464
   PubMed Web of Science ®Google Scholar
• BlairCKCerhanJRFolsomARRossJAAnthropometric characteristics and risk of multiple myelomaEpidemiology200516569169416135948
   PubMed Web of Science ®Google Scholar
• BrownLMGridleyGPottemLMDiet and nutrition as risk factors for multiple myeloma among blacks and whites in the United StatesCancer Causes Control200112211712511246840
   PubMed Web of Science ®Google Scholar
• NwabukoCONnoliMAOkohDAJohnEJChukwuonyeIISurvival outcome of multiple myeloma patients on chemotherapeutic regimens in the Niger-delta NigeriaInt J Recent Sci Res20156648894893
   Google Scholar
• NwabukoCONnoliMAIgbigbiEEOkohDAChukwuonyeIISurvival outcome of double and triple-only combination anti-myeloma chemotherapeutic regimens on 26 multiple myeloma patients seen in a Sub-Saharan African CountryBlood20141245755 ASH Abstract, 2014
   Web of Science ®Google Scholar
• International Myeloma Working GroupCriteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working GroupBr J Haematol2003121574975712780789
   PubMed Web of Science ®Google Scholar
• KyleRADurieBGRajkumarSVMonoclonal gammopathies of undetermined significance (MGUS) and smouldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and managementLeukaemia201024611211127
   PubMed Web of Science ®Google Scholar
• SepulvedaCMarlinAYoshidaTUlrichAPalliative care: the World Health Organisation’s global perspectiveJ Pain Symptom Manage200224919612231124
   PubMed Web of Science ®Google Scholar
• NwabukoCONnoliMAThe benefits of antiretroviral therapy in palliative care in developing nationsIOSR J Environ Sci Toxicol Food Technol2013267274
   Google Scholar
• Federal Republic of NigeriaNiger Delta Regional Development Master Plan Available from http://www.nddc.gov.ng/NDRMP%20Chapter%201.pdfAccessed May 11, 2017
   Google Scholar
• OkenMMCreechRHTormeyDCToxicity and response criteria of the Eastern Cooperative Oncology GroupAm J Clin Oncol1982566496557165009
   PubMed Web of Science ®Google Scholar
• EvangelosTAminRMyelomaHoffbrandAVCatovskyDTuddenhamEGPostgraduate Haematology5th edOxfordBlackwell2005681702
   Google Scholar
• DurieBGMSalmonSEA clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survivalCancer19753638428541182674
   PubMed Web of Science ®Google Scholar
• NwabukoCONnoliMAIgbigbiEEPlasma cell myeloma: challenges in diagnosis in sub-Saharan AfricaJokull J2015651254266
   Google Scholar
• SalawuLDurosimiMAMyelomatosis: clinical and laboratory features in NigeriaWest Afr J Med2005241545715909712
   PubMedGoogle Scholar
• MaduAJOchenisSNwaghaTAIbegbulamOGAnikeUSMultiple myeloma in Nigeria: an insight to the clinical, laboratory features, and outcomesNiger J Clin Pract201417221221724553034
   PubMed Web of Science ®Google Scholar
• GarretJRDurieBGMNedwinGEProduction of lymphotoxin, a bone resorbing cytokine by cultured human myeloma cellsN Eng J Med19893179526532
   Web of Science ®Google Scholar
• BeguinYYernaMLooMWeberMFilletGErythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin productionBr J Haematol19928246486531482651
   PubMed Web of Science ®Google Scholar
• OmotiCHalimNKDPlasma cell myeloma in a Tertiary Center in Niger-Delta Region of Nigeria: clinico-immunologic analysisPak J Med Sci20072312732
   Web of Science ®Google Scholar
• FasolaFAEtengKAkinyemiJOMultiple myeloma: challenges of management in a developing countryJ Med Med Sci2008397403
   Google Scholar
• DispenzieriAKyleRAMultiple myeloma: clinical features and indications for therapyBest Pract Res Clin Haematol200518455356816026737
   PubMed Web of Science ®Google Scholar
• KarMRoyRChakrabortyJDasSExtramedullary plasmacytoma-a rare presentationJournal, Indian Academy of Clinical Medicine200894229
   Google Scholar
• NwabukoCONnoliMAOkohDAChukwuonyeIITaming the tide of HIV and TTI Scourge in sub-Saharan Africa using autologous blood transfusionHaematol Leukemia20131710.7243/2052-434x-1-7
   Google Scholar
• EvangelosTGarethMMeletiosADInternational Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone diseaseJ Clin Oncol201331182347235723690408
   PubMed Web of Science ®Google Scholar
• BadrosABarlogieBSiegelEResults of autologous stem cell transplant in multiple myeloma patients with renal failureBr J Haematol2001114482282911564069
   PubMed Web of Science ®Google Scholar
• JoanBLauraRRenal, haematologic and infections complications in multiple myelomaBest Pract Res Clin Haematol200518463565216026742
   PubMed Web of Science ®Google Scholar
• FaconTMaryJYHuliuCMelphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trialLancet200737095941209121817920916
   PubMed Web of Science ®Google Scholar
• KumarSKRajkumarSVDispenzieriAImproved survival in multiple myeloma and the impact of novel therapiesBlood200811152516252017975015
   PubMed Web of Science ®Google Scholar
• RichardsonPGMitsiadesCSchlossmanRMunshiNAndersonKNew drugs for myelomaOncologist200712666468917602058
   PubMed Web of Science ®Google Scholar
• AltekruseSFKosaryCLKrapchoM webpage on the InternetSEER Cancer Statistics Review 1975–2007BethesdaNational Cancer Institute2010 Available from: seer.cancer.gov/statfacts/html/mulmy.htmlAccessed April 14, 2017
   Google Scholar
• GreippPRMiguelJSDurieBGMInternational staging system for multiple myelomaJ Clin Oncol200523153412342015809451
   PubMed Web of Science ®Google Scholar
• World Health OrganizationTraitement de la douleur cancereuseGenevaWorld health Organization1987
   Google Scholar